OCX
AMEXOncocyte Corporation
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks1+100%
2025-12-142026-06-07
Mix190d
- Leadership1(100%)
Latest news
25 items- PRInterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of DirectorsSOUTH SAN FRANCISCO, Calif., May 18, 2026 /PRNewswire/ -- InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch Levine to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases. "We are excited to welcome Alec and Mitch to InterVenn's Board of Directors at a pivotal moment fo
- INSIDERDirector Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- SECOncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECOncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oncocyte Corp (0001642380) (Filer)
- PROncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to NashvilleNew name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. ("iMDx" or the "Company"), (NASDAQ:IMDX), formerly known as Oncocyte Corporation (NASDAQ:OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company's common stock, listed on the Nasdaq Capital Market, will begin trading
- PRMedicare Boosts Reimbursement for Oncocyte's Flagship TechnologyNew price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company's position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion total addressable market. The Centers for
- SECSEC Form DEFA14A filed by Oncocyte CorporationDEFA14A - Oncocyte Corp (0001642380) (Filer)
- SECSEC Form DEF 14A filed by Oncocyte CorporationDEF 14A - Oncocyte Corp (0001642380) (Filer)
- SECSEC Form 10-Q filed by Oncocyte Corporation10-Q - Oncocyte Corp (0001642380) (Filer)
- SECOncocyte Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Oncocyte Corp (0001642380) (Filer)
- PROncocyte Reports Q1 2025 Results and Business ProgressQ1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter results: Fellow Shareholders,We're off to a fast and intensely focused start in 2025. Just two months ago, we shared our strategic outlook — and sin
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Oncocyte CorporationSCHEDULE 13G/A - Oncocyte Corp (0001642380) (Subject)
- PROncocyte to Release First Quarter 2025 Results on May 12, 2025IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di
- PROncocyte Provides Positive Update on Clinical Trial ProgressCentral Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc
- PROncocyte's Proprietary Assay Demonstrates Long-Term Clinical ValidityRobust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay. The publication, "Association of Blood Donor-derived Cell-free DNA Levels with Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational Study," is c
- PRSTAAR Surgical Announces Changes to Board of DirectorsSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to
- SECOncocyte Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Oncocyte Corp (0001642380) (Filer)
- SECSEC Form 424B3 filed by Oncocyte Corporation424B3 - Oncocyte Corp (0001642380) (Filer)
- SECSEC Form EFFECT filed by Oncocyte CorporationEFFECT - Oncocyte Corp (0001642380) (Filer)
- PROncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceIRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte's innovative diagnostic technologies and will highlight the company's progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte
- SECSEC Form S-1 filed by Oncocyte CorporationS-1 - Oncocyte Corp (0001642380) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer James Andrea S.4 - Oncocyte Corp (0001642380) (Issuer)
- INSIDERSEC Form 4 filed by VP ACCT, Cntlr, Treasurer, PAO Liu James Yang4 - Oncocyte Corp (0001642380) (Issuer)
OCX FAQ
6 questionsWhat does Oncocyte Corporation do?
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del...Where does OCX stock trade?
Oncocyte Corporation (OCX) is listed on AMEX.What sector and industry is OCX in?
Oncocyte Corporation operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about OCX?
Oncocyte Corporation has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $500.00 price target on 2025-03-28. Recent price targets range from $310.00 to $600.00.What companies are similar to OCX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare OCX side-by-side with any of them on Quantisnow.How can I track OCX on Quantisnow?
Quantisnow aggregates Oncocyte Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OCX to receive live email and push alerts on every new disclosure.